|
Groups
| |
Placebo
|
OA
|
OAC
|
(Total)
|
|---|
|
CLR use history
| |
-
|
-
|
+
| |
|
Case No.
| |
310
|
307
|
153
|
770
|
|
Sex ratio (M:F)
| |
1:1.00
|
1:1.13
|
1:0.82
|
1:1.01
|
|
Age (yrs) (Mean ± SD)
| |
45.3 ± 8.4
|
45.0 ± 8.4
|
45.7 ± 8.6
|
45.2 ± 8.5
|
|
H. pylori-positive rate in 2003 (%)
|
13C-UBT
|
90.6 (280/309)
|
54.11 (166/307)
|
53.3 (81/152)
|
68.1 (527/768)
|
| |
ELISA
|
92.5 (283/306)
|
62.11 (185/298)
|
44.12 (64/145)
|
71.0 (532/749)
|
| |
23S rRNA
|
83.9 (260/310)
|
51.11 (157/307)
|
26.82 (41/153)
|
59.5 (458/770)
|
|
Proportion of 2143G-positive H. pylori (%)
|
Total CLRr
|
13.8 (36/260)
|
10.2 (16/157)
|
31.73 (13/41)
|
14.2 (65/458)
|
| |
CLRr & s
|
9.6 (25/260)
|
6.4 (10/157)
|
14.6 (6/41)
|
9.0 (41/458)
|
|
Proportion of MboII-RFLP-positive H. pylori (%)
|
2222CTTCA
|
0.4 (1/260)
|
1.9 (3/157)
|
4.94 (2/41)
|
1.3 (6/458)
|
| |
2081GAAG
|
1.9 (5/260)
|
1.3 (2/157)
|
14.65 (4/41)
|
2.4 (11/458)
|
- 1: OA group vs. placebo group, p < 0.0000;
- 2: OAC group vs. OA group, p < 0.0005;
- 3: OAC group vs. OA group, OR = 4.09, 95%CI [1.64–10.23]; OAC group vs. placebo group, OR = 2.89, 95%CI [1.28–6.46];
- 4: OAC group vs. OA group, OR = 2.63, 95%CI [0.30–20.29]; OAC group vs. placebo group, OR = 13.28, 95%CI [0.91–379];
- 5: OAC group vs. OA group, OR = 8.38, 95%CI [1.25–68.84]; OAC group vs. placebo group, OR = 5.51, 95%CI [1.18–25.12]
